SCYNEXIS, Inc. (SCYX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

SCYNEXIS, Inc. (SCYX) Healthcare & Pipeline Overview

SCYNEXIS, Inc. is a biotechnology firm specializing in the development of treatments for fungal infections, with BREXAFEMME targeting the VVC market. The company focuses on addressing unmet needs in both recurrent and invasive fungal infections through novel oral and intravenous therapies.

What Is the Investment Thesis for SCYX?

SCYNEXIS presents a focused investment opportunity within the antifungal therapeutics market. The company's primary value driver is BREXAFEMME, an approved treatment for VVC, and the potential expansion of ibrexafungerp into broader indications, including invasive fungal infections. A key growth catalyst is the successful completion of ongoing clinical trials for the IV formulation of ibrexafungerp, which could significantly expand its market reach. With a gross margin of 100.0%, SCYNEXIS has the potential for strong profitability as revenue scales. However, the company's negative profit margin of -41.8% indicates current challenges in achieving profitability. Investors should monitor the progress of clinical trials, regulatory approvals, and commercialization efforts for ibrexafungerp, as well as the company's ability to manage its operating expenses and achieve sustainable profitability.

Based on FMP financials and quantitative analysis

SCYX Key Highlights

BREXAFEMME is approved for the treatment of vulvovaginal candidiasis (VVC), providing a revenue stream for SCYNEXIS.

• Ibrexafungerp is being developed as a novel oral and intravenous drug for various fungal infections, expanding its potential market.
• Gross margin of 100.0% indicates strong potential profitability as revenue increases.
• Research collaborations with Merck Sharp & Dohme Corp., Hansoh, and R-Pharm provide opportunities for global expansion and development.
• Completed Phase 3 CANDLE study for the prevention of recurrent VVC, potentially expanding the label for BREXAFEMME.

Who Are SCYX's Competitors?

SCYX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SCYX's Key Strengths?

Novel antifungal agent (ibrexafungerp) with a unique mechanism of action.

• Approved product (BREXAFEMME) for the treatment of VVC.
• Strategic collaborations with major pharmaceutical companies.
• Strong intellectual property protection.

What Are SCYX's Weaknesses?

Limited commercial infrastructure.

• Reliance on a single product for revenue.
• Negative profit margin.
• Small number of employees.

What Could Drive SCYX Stock Higher?

Potential FDA approval for the IV formulation of ibrexafungerp for invasive fungal infections.

• Progress in clinical trials for ibrexafungerp in additional indications.
• Expansion of commercialization efforts for BREXAFEMME in the US market.
• Development and execution of strategic partnerships for global expansion.

What Are the Key Risks for SCYX?

Financial-distress signal — its Altman Z-Score of -4.37 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-57.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for ibrexafungerp.
• Competition from established antifungal therapies.
• Dependence on a single product for revenue.
• Challenges in achieving profitability.
• Unfavorable clinical trial results.

What Are the Growth Opportunities for SCYX?

• Expansion of Ibrexafungerp into Invasive Fungal Infections: SCYNEXIS has the opportunity to expand the use of ibrexafungerp beyond VVC to treat more severe, life-threatening invasive fungal infections, such as invasive aspergillosis and candidiasis. The market for invasive fungal infection treatments is substantial, driven by the increasing number of immunocompromised patients. Successful clinical trials and regulatory approvals for the IV formulation of ibrexafungerp could significantly increase SCYNEXIS's revenue potential.
• Commercialization in International Markets: Through its collaborations with Hansoh, R-Pharm and Merck, SCYNEXIS has the opportunity to commercialize ibrexafungerp in key international markets, including China and Russia. These partnerships provide access to established distribution networks and regulatory expertise, accelerating the market entry process. The global antifungal market is growing, and expanding into these regions could provide a significant revenue boost.
• Lifecycle Management of BREXAFEMME: SCYNEXIS can extend the lifecycle of BREXAFEMME through various strategies, such as developing new formulations, expanding the label to include additional indications, and securing patent extensions. The completion of the Phase 3 CANDLE study for the prevention of recurrent VVC could lead to a label expansion, increasing the drug's market potential and extending its revenue stream.
• Development of New Antifungal Therapies: SCYNEXIS can leverage its expertise in antifungal drug development to discover and develop new therapies targeting emerging fungal pathogens and drug-resistant strains. Investing in research and development to expand its pipeline of antifungal candidates could provide long-term growth opportunities and diversify its revenue streams.
• Strategic Acquisitions and Partnerships: SCYNEXIS can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, and strengthen its market position. Acquiring or partnering with companies that have complementary assets or expertise in the antifungal space could accelerate its growth and create synergies.

What Threats Does SCYX Face?

• Competition from established antifungal therapies.
• Regulatory hurdles and delays.
• Patent expiration.
• Generic entry.

What Are SCYX's Competitive Advantages?

• Novel Mechanism of Action: Ibrexafungerp represents a novel class of antifungals with a differentiated mechanism of action compared to existing treatments, potentially offering advantages in treating resistant fungal strains.
• Patent Protection: SCYNEXIS holds patents covering ibrexafungerp and its formulations, providing exclusivity and protecting its market position.
• Established Partnerships: Collaborations with Merck, Hansoh, and R-Pharm provide access to resources, expertise, and distribution networks, strengthening its competitive position.

What Does SCYX Do?

SCYNEXIS, Inc., founded in 1999 and headquartered in Jersey City, New Jersey, is a biotechnology company dedicated to discovering, developing, and commercializing innovative solutions for the prevention and treatment of fungal infections. Originally named SCYNEXIS Chemistry & Automation, Inc., the company rebranded in 2002 to reflect its focus on broader pharmaceutical development. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal medication approved for the treatment of vulvovaginal candidiasis (VVC), commonly known as yeast infections. SCYNEXIS is also developing ibrexafungerp as a novel intravenous (IV) formulation to address a range of severe fungal infections, including invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Ibrexafungerp represents a novel class of antifungals, offering a differentiated mechanism of action compared to existing treatments. SCYNEXIS has established research collaborations with pharmaceutical companies such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC, to develop and commercialize ibrexafungerp in various global markets. SCYNEXIS continues to focus on expanding the clinical utility of ibrexafungerp through ongoing clinical trials and exploring new indications.

What Products and Services Does SCYX Offer?

• Develop and commercialize products for the treatment of fungal infections.
• Offer BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC).
• Develop ibrexafungerp as a novel oral and intravenous drug for various fungal infections.
• Conduct clinical trials to evaluate the safety and efficacy of ibrexafungerp.
• Collaborate with pharmaceutical companies to develop and commercialize ibrexafungerp globally.
• Focus on addressing unmet needs in both recurrent and invasive fungal infections.

How Does SCYX Make Money?

• Develop and commercialize proprietary antifungal drugs.
• Generate revenue through the sale of BREXAFEMME.
• Establish partnerships with other pharmaceutical companies for development and commercialization rights.
• Pursue research and development to expand the pipeline of antifungal therapies.

What Industry Does SCYX Operate In?

SCYNEXIS operates in the specialty pharmaceutical sector, specifically targeting the antifungal market. This market is driven by the increasing prevalence of fungal infections, particularly in immunocompromised patients. The competitive landscape includes established pharmaceutical companies and generic drug manufacturers offering existing antifungal therapies. SCYNEXIS differentiates itself through its novel ibrexafungerp, which offers a new mechanism of action and potential advantages in treating resistant fungal strains. The antifungal market is expected to grow due to factors such as increasing global travel, which can spread fungal infections, and the rising use of immunosuppressant drugs.

Who Are SCYX's Key Customers?

• Women suffering from vulvovaginal candidiasis (VVC).
• Hospitals and healthcare providers treating patients with invasive fungal infections.
• Pharmaceutical companies partnering with SCYNEXIS for development and commercialization.

SCYNEXIS, Inc. Financial Trajectory

SCYNEXIS, Inc. (SCYX) reported $235K in revenue for Q2 2026, a decline of 98.7% compared to the prior quarter. The company recorded net income of $7.4M, with diluted EPS of $0.63. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.

Company Profile

SCYNEXIS, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Jersey City, US. The company is led by CEO David Angulo. SCYX has traded publicly since 2014.

How SCYNEXIS, Inc. Is Valued

SCYNEXIS, Inc. carries a market capitalization of $32.8M, placing it in the micro-cap category. Relative to its peer group, SCYX's quantitative score of 22/100 is below the peer average of 66/100.

Return on equity for SCYNEXIS, Inc. stands at -57.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -31.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.94 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -87.1%, the inverse of the P/E and a quick read on earnings relative to price.

SCYNEXIS, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.37 places it in the distress zone, a signal of elevated financial risk.

SCYNEXIS, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 444.2% below estimates on average.

Wall Street analysts project SCYNEXIS, Inc. revenue of about $1.2M for fiscal 2026, with EPS near $-3.25.

SCYX Financials

SCYX Latest News

SCYX Analyst Consensus

SCYX MoonshotScore

What Investors Ask About SCYNEXIS, Inc. (SCYX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources